![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: BRD2 |
Gene summary for BRD2 |
![]() |
Gene information | Species | Human | Gene symbol | BRD2 | Gene ID | 6046 |
Gene name | bromodomain containing 2 | |
Gene Alias | BRD2-IT1 | |
Cytomap | 6p21.32 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024RCR5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6046 | BRD2 | GSM4909285 | Human | Breast | IDC | 9.03e-06 | -7.77e-02 | 0.21 |
6046 | BRD2 | GSM4909286 | Human | Breast | IDC | 8.36e-08 | -1.30e-01 | 0.1081 |
6046 | BRD2 | GSM4909291 | Human | Breast | IDC | 6.90e-16 | 6.16e-01 | 0.1753 |
6046 | BRD2 | GSM4909293 | Human | Breast | IDC | 1.59e-06 | 1.23e-01 | 0.1581 |
6046 | BRD2 | GSM4909294 | Human | Breast | IDC | 1.20e-07 | -4.47e-01 | 0.2022 |
6046 | BRD2 | GSM4909296 | Human | Breast | IDC | 1.65e-04 | -2.54e-01 | 0.1524 |
6046 | BRD2 | GSM4909297 | Human | Breast | IDC | 1.79e-06 | -1.31e-01 | 0.1517 |
6046 | BRD2 | GSM4909298 | Human | Breast | IDC | 7.08e-06 | 7.17e-02 | 0.1551 |
6046 | BRD2 | GSM4909302 | Human | Breast | IDC | 2.99e-03 | -3.46e-01 | 0.1545 |
6046 | BRD2 | GSM4909311 | Human | Breast | IDC | 9.96e-19 | -4.28e-01 | 0.1534 |
6046 | BRD2 | GSM4909312 | Human | Breast | IDC | 1.11e-03 | 2.77e-02 | 0.1552 |
6046 | BRD2 | GSM4909315 | Human | Breast | IDC | 4.12e-02 | -3.03e-01 | 0.21 |
6046 | BRD2 | GSM4909316 | Human | Breast | IDC | 1.79e-02 | -4.21e-01 | 0.21 |
6046 | BRD2 | GSM4909319 | Human | Breast | IDC | 1.54e-29 | -4.66e-01 | 0.1563 |
6046 | BRD2 | GSM4909320 | Human | Breast | IDC | 3.00e-03 | -2.92e-01 | 0.1575 |
6046 | BRD2 | GSM4909321 | Human | Breast | IDC | 7.73e-12 | 3.19e-01 | 0.1559 |
6046 | BRD2 | brca1 | Human | Breast | Precancer | 1.53e-03 | -3.11e-01 | -0.0338 |
6046 | BRD2 | brca2 | Human | Breast | Precancer | 1.62e-04 | -2.20e-01 | -0.024 |
6046 | BRD2 | brca3 | Human | Breast | Precancer | 2.47e-05 | -1.47e-01 | -0.0263 |
6046 | BRD2 | brca10 | Human | Breast | Precancer | 4.09e-06 | -4.27e-01 | -0.0029 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00606065 | Prostate | BPH | tube closure | 25/3107 | 89/18723 | 4.43e-03 | 2.17e-02 | 25 |
GO:00219157 | Prostate | BPH | neural tube development | 38/3107 | 152/18723 | 5.14e-03 | 2.42e-02 | 38 |
GO:006056214 | Prostate | Tumor | epithelial tube morphogenesis | 90/3246 | 325/18723 | 1.93e-06 | 3.34e-05 | 90 |
GO:000632514 | Prostate | Tumor | chromatin organization | 104/3246 | 409/18723 | 2.02e-05 | 2.62e-04 | 104 |
GO:001633112 | Prostate | Tumor | morphogenesis of embryonic epithelium | 45/3246 | 147/18723 | 5.34e-05 | 5.83e-04 | 45 |
GO:003514814 | Prostate | Tumor | tube formation | 45/3246 | 148/18723 | 6.41e-05 | 6.95e-04 | 45 |
GO:000183813 | Prostate | Tumor | embryonic epithelial tube formation | 38/3246 | 121/18723 | 1.09e-04 | 1.03e-03 | 38 |
GO:000184112 | Prostate | Tumor | neural tube formation | 33/3246 | 102/18723 | 1.60e-04 | 1.44e-03 | 33 |
GO:007217512 | Prostate | Tumor | epithelial tube formation | 39/3246 | 132/18723 | 3.66e-04 | 2.86e-03 | 39 |
GO:001402012 | Prostate | Tumor | primary neural tube formation | 29/3246 | 94/18723 | 9.27e-04 | 6.10e-03 | 29 |
GO:000184312 | Prostate | Tumor | neural tube closure | 27/3246 | 88/18723 | 1.50e-03 | 9.25e-03 | 27 |
GO:000633811 | Prostate | Tumor | chromatin remodeling | 63/3246 | 255/18723 | 1.73e-03 | 1.02e-02 | 63 |
GO:006060612 | Prostate | Tumor | tube closure | 27/3246 | 89/18723 | 1.80e-03 | 1.06e-02 | 27 |
GO:002191512 | Prostate | Tumor | neural tube development | 41/3246 | 152/18723 | 1.91e-03 | 1.12e-02 | 41 |
GO:000632519 | Skin | cSCC | chromatin organization | 147/4864 | 409/18723 | 4.41e-06 | 6.52e-05 | 147 |
GO:000633812 | Skin | cSCC | chromatin remodeling | 94/4864 | 255/18723 | 7.58e-05 | 7.26e-04 | 94 |
GO:00718241 | Skin | cSCC | protein-DNA complex subunit organization | 87/4864 | 241/18723 | 3.09e-04 | 2.47e-03 | 87 |
GO:001402015 | Skin | cSCC | primary neural tube formation | 39/4864 | 94/18723 | 7.37e-04 | 5.15e-03 | 39 |
GO:000184315 | Skin | cSCC | neural tube closure | 37/4864 | 88/18723 | 7.39e-04 | 5.15e-03 | 37 |
GO:006060615 | Skin | cSCC | tube closure | 37/4864 | 89/18723 | 9.52e-04 | 6.47e-03 | 37 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BRD2 | SNV | Missense_Mutation | novel | c.2348N>G | p.Asn783Ser | p.N783S | P25440 | protein_coding | tolerated(0.08) | probably_damaging(0.97) | TCGA-E9-A3QA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BRD2 | insertion | Nonsense_Mutation | novel | c.2480_2481insCTGATAAAT | p.Ser827_Ser828insTer | p.S827_S828ins* | P25440 | protein_coding | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
BRD2 | deletion | Frame_Shift_Del | novel | c.184_185delCC | p.Pro62ThrfsTer65 | p.P62Tfs*65 | P25440 | protein_coding | TCGA-E9-A3HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR | ||
BRD2 | SNV | Missense_Mutation | novel | c.1556G>A | p.Arg519His | p.R519H | P25440 | protein_coding | tolerated(0.06) | possibly_damaging(0.883) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
BRD2 | SNV | Missense_Mutation | novel | c.101N>C | p.Arg34Pro | p.R34P | P25440 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
BRD2 | SNV | Missense_Mutation | c.596N>A | p.Gly199Glu | p.G199E | P25440 | protein_coding | tolerated(0.13) | benign(0.316) | TCGA-FU-A3YQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
BRD2 | SNV | Missense_Mutation | novel | c.292N>T | p.Pro98Ser | p.P98S | P25440 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
BRD2 | SNV | Missense_Mutation | novel | c.950G>A | p.Arg317His | p.R317H | P25440 | protein_coding | deleterious(0) | possibly_damaging(0.895) | TCGA-VS-A9UJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
BRD2 | SNV | Missense_Mutation | c.964N>T | p.Arg322Cys | p.R322C | P25440 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
BRD2 | SNV | Missense_Mutation | c.1444N>G | p.Ser482Gly | p.S482G | P25440 | protein_coding | tolerated(0.32) | benign(0.017) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6046 | BRD2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | TRIAZOLAM | TRIAZOLAM | 22137933 | |
6046 | BRD2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | Pyrrolo-pyrrolone derivative 1 | |||
6046 | BRD2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 187051820 | ||
6046 | BRD2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | PMID26924192-Compound-102 | |||
6046 | BRD2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | PMID26924192-Compound-103 | |||
6046 | BRD2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 187051816 | CHEMBL2153434 | |
6046 | BRD2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | OTX-015 | BIRABRESIB | ||
6046 | BRD2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | ALPRAZOLAM | ALPRAZOLAM | 22137933 | |
6046 | BRD2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 187051823 | ||
6046 | BRD2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 187051818 |
Page: 1 2 3 |